Literature DB >> 15480106

Nebivolol improves coronary flow reserve in hypertensive patients without coronary heart disease.

Maurizio Galderisi1, Silvana Cicala, Arcangelo D'Errico, Oreste de Divitiis, Giovanni de Simone.   

Abstract

OBJECTIVE: To examine the effects of nebivolol, a beta-blocker with nitroxide-mediated vasodilating properties, on coronary flow reserve (CFR) in patients with uncomplicated arterial hypertension. DESIGN, SETTING AND PATIENTS: Fourteen newly diagnosed, never-treated, World Health Organization grade I-II hypertensive patients (male/female, 10/4; mean age, 47 years), free of coronary heart disease, underwent standard Doppler echocardiography and determination of CFR in the distal left anterior descending artery by low-dose dipyridamole (0.56 mg/kg intravenously in 4 min) at baseline and after 4 weeks of treatment with 5 mg nebivolol once daily.
RESULTS: At baseline, nine patients had left ventricular (LV) hypertrophy (LV mass index > or = 51 g/m). After 4 weeks of therapy, the blood pressure was decreased from 148 +/- 8.1/101.4 +/- 4.6 mmHg to 140.7 +/- 7.0/91.1 +/- 7.4 mmHg and end-systolic stress was also significantly reduced. Heart rate was reduced (P <0.01), whereas LV end-diastolic diameter and stroke volume tended to increase (P=0.07 and P=0.09, respectively). No changes were detected in the LV mass index, relative wall thickness, fractional shortening and LV diastolic properties. Both resting and dipyridamole rate-pressure products were lower after nebivolol but dipyridamole-induced changes were not influenced by the therapy. In contrast, nebivolol therapy did not alter coronary velocities at rest, but caused a greater increase in coronary velocities after dipyridamole (P <0.03), leading to a greater CFR (2.12 +/- 0.33 versus 1.89 +/- 0.31, P <0.0001). Nebivolol induced an absolute increase of 8% in the CFR in nine of 14 patients (64.3%).
CONCLUSIONS: In hypertensive patients free of coronary artery disease, 4-week nebivolol therapy induces a significant increase of the CFR. Nebivolol preserves coronary flow at rest despite the reduction of metabolic (O2 consumption) and hemodynamic (diastolic blood pressure) determinants. The increase of hyperemic coronary velocities appears due to the reduction of coronary resistance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15480106     DOI: 10.1097/00004872-200411000-00024

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  17 in total

1.  Different effects of atenolol and nebivolol on coronary flow reserve.

Authors:  H Gullu; D Erdogan; M Caliskan; D Tok; I Yildirim; A T Sezgin; H Muderrisoglu
Journal:  Heart       Date:  2006-11       Impact factor: 5.994

Review 2.  The vasodilatory beta-blockers.

Authors:  Michala E Pedersen; John R Cockcroft
Journal:  Curr Hypertens Rep       Date:  2007-08       Impact factor: 5.369

3.  Myocardial flow reserve is influenced by both coronary artery stenosis severity and coronary risk factors in patients with suspected coronary artery disease.

Authors:  Takahiro Tsukamoto; Koichi Morita; Masanao Naya; Chietsugu Katoh; Masayuki Inubushi; Yuji Kuge; Hiroyuki Tsutsui; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-05-30       Impact factor: 9.236

4.  Nebivolol improves coronary flow reserve in patients with idiopathic dilated cardiomyopathy.

Authors:  Dogan Erdogan; Hakan Gullu; Mustafa Caliskan; Ozgur Ciftci; Semra Baycan; Aylin Yildirir; Haldun Muderrisoglu
Journal:  Heart       Date:  2006-10-25       Impact factor: 5.994

Review 5.  Coronary Flow Velocity Reserve Assessment with Transthoracic Doppler Echocardiography.

Authors:  Iana Simova
Journal:  Eur Cardiol       Date:  2015-07

Review 6.  Beta-blockers and coronary flow reserve: the importance of a vasodilatory action.

Authors:  Maurizio Galderisi; Arcangelo D'Errico
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 7.  Coronary Microvascular Dysfunction: A Practical Approach to Diagnosis and Management.

Authors:  Daria Frestad Bechsgaard; Eva Prescott
Journal:  Curr Atheroscler Rep       Date:  2021-07-16       Impact factor: 5.113

Review 8.  Diastolic heart failure in hypertension: possible preventive benefits of nebivolol beyond lowering blood pressure.

Authors:  Natalia Patrascu
Journal:  Maedica (Buchar)       Date:  2013-09

9.  Effects of isoflurane on coronary blood flow velocity in young, old and ApoE(-/-) mice measured by Doppler ultrasound.

Authors:  Craig J Hartley; Anilkumar K Reddy; Sridhar Madala; Lloyd H Michael; Mark L Entman; George E Taffet
Journal:  Ultrasound Med Biol       Date:  2007-04       Impact factor: 2.998

10.  Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release.

Authors:  Otto Kamp; Marco Metra; Silvia Bugatti; Luca Bettari; Alessandra Dei Cas; Natalia Petrini; Livio Dei Cas
Journal:  Drugs       Date:  2010       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.